959 related articles for article (PubMed ID: 34009000)
21. Axillary Lymphadenopathy after Pfizer-BioNTech and Moderna COVID-19 Vaccination: MRI Evaluation.
Yoshikawa T; Miki S; Nakao T; Koshino S; Hayashi N; Abe O
Radiology; 2023 Jan; 306(1):270-278. PubMed ID: 36098641
[TBL] [Abstract][Full Text] [Related]
22. Temporary Reactive Response of Axillary Lymph Nodes to COVID-19 Vaccination on
Notohamiprodjo S; Eiber M; Lohrmann C; Weber WA
J Nucl Med; 2022 Nov; 63(11):1673-1676. PubMed ID: 35241484
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 Vaccination-Associated Lymphadenopathy on FDG PET/CT: Distinctive Features in Adenovirus-Vectored Vaccine.
Shin M; Hyun CY; Choi YH; Choi JY; Lee KH; Cho YS
Clin Nucl Med; 2021 Oct; 46(10):814-819. PubMed ID: 34115709
[TBL] [Abstract][Full Text] [Related]
24. Lessons Learned from Post-COVID-19 Vaccination PET/CT Studies.
Orevi M; Chicheportiche A; Ben Haim S
J Nucl Med; 2022 Mar; 63(3):453-460. PubMed ID: 34301777
[TBL] [Abstract][Full Text] [Related]
25. COVID-19 mRNA Vaccination-Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT.
Xu G; Lu Y
Clin Nucl Med; 2021 Apr; 46(4):353-354. PubMed ID: 33591026
[TBL] [Abstract][Full Text] [Related]
26. Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of COVID-19 Vaccination.
Edmonds CE; Zuckerman SP; Conant EF
AJR Am J Roentgenol; 2021 Oct; 217(4):831-834. PubMed ID: 33543649
[TBL] [Abstract][Full Text] [Related]
27. The incidence and duration of COVID-19 vaccine-related reactive lymphadenopathy on
El-Sayed MS; Wechie GN; Low CS; Adesanya O; Rao N; Leung VJ
Clin Med (Lond); 2021 Nov; 21(6):e633-e638. PubMed ID: 34862224
[TBL] [Abstract][Full Text] [Related]
28. Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT: A Cohort Study.
Bernstine H; Priss M; Anati T; Turko O; Gorenberg M; Steinmetz AP; Groshar D
Clin Nucl Med; 2021 May; 46(5):396-401. PubMed ID: 33782299
[TBL] [Abstract][Full Text] [Related]
29. DOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination.
Brophy J; Henkle G; Rohren EM
Clin Nucl Med; 2022 Feb; 47(2):174-175. PubMed ID: 34269723
[TBL] [Abstract][Full Text] [Related]
30. Morphological and Metabolic Criteria of COVID-19 Vaccine Associated Axillary Nodes on 18-Fluorodeouxyglucose PET/CT Imaging in Breast Cancer Patients.
Fatima N; Zaman U; Zaman A; Zaman S; Tahseen R; Zaman MU
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4053-4057. PubMed ID: 38156837
[TBL] [Abstract][Full Text] [Related]
31. Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine.
Burger IA; Husmann L; Hany TF; Schmid DT; Schaefer NG
Clin Nucl Med; 2011 Oct; 36(10):848-53. PubMed ID: 21892032
[TBL] [Abstract][Full Text] [Related]
32. FDG-Avid Ipsilateral Iliac and Inguinal Lymphadenopathy After COVID-19 Vaccination With Thigh Injection.
Bass D; Puri S
AJR Am J Roentgenol; 2022 Jan; 218(1):180. PubMed ID: 34259040
[No Abstract] [Full Text] [Related]
33. Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on
Chiang MT; Wang JT; Lin WY; Yen RF; Huang JY; Lu CC
Eur J Med Res; 2023 Nov; 28(1):513. PubMed ID: 37964395
[TBL] [Abstract][Full Text] [Related]
34. Unilateral axillary adenopathy induced by COVID-19 vaccine: US follow-up evaluation.
Igual-Rouilleault AC; Soriano I; Quan PL; Fernández-Montero A; Elizalde A; Pina L
Eur Radiol; 2022 May; 32(5):3199-3206. PubMed ID: 34655312
[TBL] [Abstract][Full Text] [Related]
35. Time for Resolution of COVID-19 Vaccine-Related Axillary Lymphadenopathy and Associated Factors.
Lane EG; Eisen CS; Drotman MB; Dodelzon K; Mema E; Thomas C; Prince MR
AJR Am J Roentgenol; 2022 Oct; 219(4):559-568. PubMed ID: 35583425
[No Abstract] [Full Text] [Related]
36. COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases.
Faermann R; Nissan N; Halshtok-Neiman O; Shalmon A; Gotlieb M; Yagil Y; Samoocha D; Friedman E; Sklair-Levy M
Acad Radiol; 2021 Sep; 28(9):1191-1197. PubMed ID: 34257025
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Myocardial
Nakahara T; Iwabuchi Y; Miyazawa R; Tonda K; Shiga T; Strauss HW; Antoniades C; Narula J; Jinzaki M
Radiology; 2023 Sep; 308(3):e230743. PubMed ID: 37724969
[TBL] [Abstract][Full Text] [Related]
38. Evolving Bilateral Hypermetabolic Axillary Lymphadenopathy on FDG PET/CT Following 2-Dose COVID-19 Vaccination.
Weeks JK; O'Brien SR; Rosenspire KC; Dubroff JG; Pantel AR
Clin Nucl Med; 2021 Dec; 46(12):1011-1012. PubMed ID: 34735411
[TBL] [Abstract][Full Text] [Related]
39. Comparison between viral vector and mRNA based COVID-19 vaccination in prevalence and severity of regional immune reactions, and
Ayati N; Evans S; Zakavi SR; Gruenewald SM
Asia Ocean J Nucl Med Biol; 2023; 11(1):4-12. PubMed ID: 36619184
[TBL] [Abstract][Full Text] [Related]
40. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
